The European Commission faced criticism from the EU General Court for insufficient public access to COVID-19 vaccine purchase agreements with pharmaceutical companies, leading to legal action by EU lawmakers. The court highlighted issues regarding transparency in negotiations and the Commission's handling of contracts that were redacted and lacked full disclosure. Despite the Commission's role in joint vaccine procurement for EU member states, it failed to provide comprehensive information on costs and full details of agreements, potentially impacting transparency and accountability. This ruling coincides with a vote in the European Parliament on the reelection of Commission President Ursula von der Leyen, emphasizing the ongoing scrutiny and challenges surrounding COVID-19 vaccine procurement transparency.